RET and thyroid cancer: In accordance with the pivotal role of RET in regulating the growth of thyroid cancer cells in tumor development, there are clinically available drugs for MTC therapy such as cabozantinib and vandetanib that inhibit the tyrosine kinase activity of RET [13–16].